AZN | AstraZeneca PLC Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	71.31 - 72.57
52 Week Range	61.24 - 87.68
Beta	0.40
Implied Volatility	34.59%
IV Rank	53.90%
Day's Volume	4,055,978
Average Volume	6,252,116
Shares Outstanding	6,200,719,771
Market Cap	445,149,672,360
Sector	Healthcare
Industry	Drug Manufacturers - General
IPO Date	1993-05-12

Valuation
Profitability
Growth
Health
P/E Ratio	31.91
Forward P/E Ratio	19.63
EPS	2.25
1YR Price Target	79.50
Dividend Yield	3.09%
Dividend Per Share	2.22
Dividend ExDate	2022-08-11
Dividend PayDate	2022-09-12
Employees	89,900
Country	UK
Website	AZN

A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, immunology and rare diseases. The majority of sales come from international markets with the United States representing close to one third of its sales.

AZN's peers: AMRN, NVS, GSK, RHHBY, BMY, SNY, MRK, GILD, JNJ, ABBV, LLY, PFE, AMGN, GRFS, NVAX, OGN, SCLX

*Chart delayed

Analyzing fundamentals for AZN we got that it has average fundamentals where Valuation is considered to be fairly valued, Profitability is very poor, Growth is exceptionally good and Health is very weak. For more detailed analysis please see AZN Fundamentals page.

Watching at AZN technicals we can see that long-term trend is bearish, while middle-term trend is bullish, but short-term trend is bearish. More technicals details can be found on AZN Technicals page.